Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$92.38
-0.39-0.42%
At close: -
$92.38
0.000.00%
After Hours: Mar 21, 4:02 PM EDT
Comments
Loading...
Amedisys Analyst Ratings and Price Targets | NASDAQ:AMED | Benzinga
Amedisys Inc has a consensus price target of $111.48 based on the ratings of 24 analysts. The high is $182 issued by Credit Suisse on April 29, 2022. The low is $85 issued by SVB Leerink on January 5, 2023. The 3 most-recent analyst ratings were released by Stephens & Co., Stephens & Co., and Deutsche Bank on March 4, 2025, February 12, 2025, and July 31, 2024, respectively. With an average price target of $101 between Stephens & Co., Stephens & Co., and Deutsche Bank, there's an implied 9.33% upside for Amedisys Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Stephens & Co.
Stephens & Co.
Deutsche Bank
Cantor Fitzgerald
RBC Capital
1calculated from analyst ratings
Analyst Ratings for Amedisys
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/04/2025 | Buy Now | 9.33% | Stephens & Co. | Scott Fidel 37% | $101 → $101 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 02/12/2025 | Buy Now | 9.33% | Stephens & Co. | Raj Kumar 38% | $101 → $101 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 07/31/2024 | Buy Now | 9.33% | Deutsche Bank | Justin Bowers51% | $101 → $101 | Downgrade | Buy → Hold | Get Alert |
| 07/25/2024 | Buy Now | 9.33% | Cantor Fitzgerald | Sarah James50% | $101 → $101 | Reiterates | Neutral → Neutral | Get Alert |
| 07/01/2024 | Buy Now | — | William Blair | Matt Larew25% | — | Downgrade | Outperform → Market Perform | Get Alert |
| 04/25/2024 | Buy Now | 9.33% | Cantor Fitzgerald | Sarah James50% | $101 → $101 | Reiterates | Neutral → Neutral | Get Alert |
| 03/26/2024 | Buy Now | — | Raymond James | John Ransom76% | — | Maintains | Market Perform | Get Alert |
| 03/25/2024 | Buy Now | 8.25% | RBC Capital | Ben Hendrix60% | $97 → $100 | Maintains | Outperform | Get Alert |
| 09/14/2023 | Buy Now | 9.33% | Cantor Fitzgerald | Sarah James50% | $100 → $101 | Maintains | Neutral | Get Alert |
| 07/31/2023 | Buy Now | 9.33% | TD Cowen | Gary Taylor59% | $84 → $101 | Maintains | Market Perform | Get Alert |
| 07/27/2023 | Buy Now | 9.33% | Credit Suisse | Jonathan Yong64% | → $101 | Reiterates | Neutral → Neutral | Get Alert |
| 07/06/2023 | Buy Now | 9.33% | Jefferies | Brian Tanquilut45% | $98 → $101 | Downgrade | Buy → Hold | Get Alert |
| 06/28/2023 | Buy Now | — | Benchmark | Bill Sutherland63% | — | Downgrade | Buy → Hold | Get Alert |
| 06/27/2023 | Buy Now | — | Benchmark | Bill Sutherland63% | — | Downgrade | Buy → Hold | Get Alert |
| 06/27/2023 | Buy Now | 9.33% | Truist Securities | David Macdonald67% | $97 → $101 | Maintains | Hold | Get Alert |
| 06/07/2023 | Buy Now | 5% | Truist Securities | David Macdonald67% | → $97 | Downgrade | Buy → Hold | Get Alert |
| 06/06/2023 | Buy Now | 8.25% | Cantor Fitzgerald | Sarah James50% | $91 → $100 | Maintains | Neutral | Get Alert |
| 06/06/2023 | Buy Now | 24.49% | Benchmark | Bill Sutherland63% | → $115 | Reiterates | Buy → Buy | Get Alert |
| 06/06/2023 | Buy Now | 8.25% | Credit Suisse | Jonathan Yong64% | $115 → $100 | Downgrade | Outperform → Neutral | Get Alert |
| 05/08/2023 | Buy Now | -9.07% | TD Cowen | Gary Taylor59% | $95 → $84 | Maintains | Market Perform | Get Alert |
| 05/05/2023 | Buy Now | -4.74% | Barclays | Steve Valiquette53% | $93 → $88 | Maintains | Equal-Weight | Get Alert |
| 05/04/2023 | Buy Now | 5% | Truist Securities | David Macdonald67% | $115 → $97 | Maintains | Buy | Get Alert |
| 05/04/2023 | Buy Now | 11.5% | Stephens & Co. | Scott Fidel68% | → $103 | Reiterates | → Equal-Weight | Get Alert |
| 04/21/2023 | Buy Now | -5.82% | Cantor Fitzgerald | Sarah James50% | → $87 | Initiates | → Neutral | Get Alert |
| 04/13/2023 | Buy Now | 24.49% | Truist Securities | David Macdonald67% | $130 → $115 | Maintains | Buy | Get Alert |
| 03/14/2023 | Buy Now | 24.49% | Benchmark | Bill Sutherland63% | → $115 | Reiterates | → Buy | Get Alert |
| 03/14/2023 | Buy Now | 11.5% | Stephens & Co. | Scott Fidel68% | → $103 | Reiterates | → Equal-Weight | Get Alert |
| 03/13/2023 | Buy Now | 0.67% | Barclays | Steve Valiquette53% | → $93 | Initiates | → Equal-Weight | Get Alert |
| 02/27/2023 | Buy Now | 24.49% | Credit Suisse | Jonathan Yong64% | → $115 | Reiterates | → Outperform | Get Alert |
| 02/21/2023 | Buy Now | 20.16% | RBC Capital | Ben Hendrix60% | $114 → $111 | Maintains | Outperform | Get Alert |
| 02/16/2023 | Buy Now | 2.84% | Stephens & Co. | Scott Fidel68% | → $95 | Reiterates | → Equal-Weight | Get Alert |
| 02/16/2023 | Buy Now | 24.49% | Benchmark | Mark Miller67% | $120 → $115 | Maintains | Buy | Get Alert |
| 02/13/2023 | Buy Now | 29.9% | Benchmark | Bill Sutherland63% | → $120 | Reiterates | → Buy | Get Alert |
| 01/25/2023 | Buy Now | 29.9% | Benchmark | Bill Sutherland63% | $135 → $120 | Maintains | Buy | Get Alert |
| 01/23/2023 | Buy Now | 24.49% | Credit Suisse | Jonathan Yong64% | $140 → $115 | Maintains | Outperform | Get Alert |
| 01/19/2023 | Buy Now | 35.31% | Oppenheimer | Colin Rusch53% | $145 → $125 | Maintains | Outperform | Get Alert |
| 01/05/2023 | Buy Now | -7.99% | SVB Leerink | Whit Mayo68% | $96 → $85 | Maintains | Market Perform | Get Alert |
| 11/11/2022 | Buy Now | 14.74% | Stephens & Co. | Scott Fidel68% | $122 → $106 | Maintains | Equal-Weight | Get Alert |
| 11/01/2022 | Buy Now | 3.92% | SVB Leerink | Whit Mayo68% | $116 → $96 | Maintains | Market Perform | Get Alert |
| 11/01/2022 | Buy Now | 32.06% | Stephens & Co. | Scott Fidel68% | $105 → $122 | Maintains | Equal-Weight | Get Alert |
| 10/31/2022 | Buy Now | 50.47% | RBC Capital | Frank Morgan45% | $165 → $139 | Maintains | Outperform | Get Alert |
| 10/28/2022 | Buy Now | 36.39% | Barclays | Sarah James50% | $154 → $126 | Maintains | Overweight | Get Alert |
| 10/28/2022 | Buy Now | 13.66% | Stephens & Co. | Scott Fidel68% | $120 → $105 | Maintains | Equal-Weight | Get Alert |
| 10/28/2022 | Buy Now | 40.72% | Truist Securities | David Macdonald67% | $140 → $130 | Maintains | Buy | Get Alert |
| 10/28/2022 | Buy Now | 56.96% | Oppenheimer | Michael Wiederhorn61% | $175 → $145 | Maintains | Outperform | Get Alert |
| 10/27/2022 | Buy Now | — | Raymond James | John Ransom76% | — | Downgrade | Outperform → Market Perform | Get Alert |
| 10/24/2022 | Buy Now | 78.61% | Deutsche Bank | Justin Bowers51% | $175 → $165 | Maintains | Buy | Get Alert |
| 10/05/2022 | Buy Now | 51.55% | Truist Securities | David Macdonald67% | $150 → $140 | Maintains | Buy | Get Alert |
| 10/03/2022 | Buy Now | 46.14% | Benchmark | Bill Sutherland63% | $165 → $135 | Maintains | Buy | Get Alert |
| 08/02/2022 | Buy Now | 2.84% | UBS | Andrew Mok54% | $145 → $95 | Downgrade | Neutral → Sell | Get Alert |
| 08/01/2022 | Buy Now | 51.55% | Raymond James | John Ransom76% | $180 → $140 | Maintains | Outperform | Get Alert |
| 07/29/2022 | Buy Now | 66.7% | Barclays | Sarah James50% | $181 → $154 | Maintains | Overweight | Get Alert |
| 07/28/2022 | Buy Now | 78.61% | Benchmark | Bill Sutherland63% | $175 → $165 | Maintains | Buy | Get Alert |
| 07/14/2022 | Buy Now | 62.37% | Truist Securities | David Macdonald67% | $175 → $150 | Maintains | Buy | Get Alert |
| 06/29/2022 | Buy Now | 38.56% | Stifel | Tao Qiu46% | → $128 | Initiates | → Hold | Get Alert |
| 06/21/2022 | Buy Now | 10.41% | B of A Securities | Joanna Gajuk61% | $145 → $102 | Downgrade | Neutral → Underperform | Get Alert |
| 06/21/2022 | Buy Now | 89.43% | Deutsche Bank | Justin Bowers51% | $210 → $175 | Maintains | Buy | Get Alert |
| 06/21/2022 | Buy Now | 89.43% | Truist Securities | David Macdonald67% | $200 → $175 | Maintains | Buy | Get Alert |
| 06/21/2022 | Buy Now | 35.31% | Stephens & Co. | Scott Fidel68% | $155 → $125 | Maintains | Equal-Weight | Get Alert |
| 06/21/2022 | Buy Now | 15.83% | SVB Leerink | Whit Mayo68% | $117 → $107 | Maintains | Market Perform | Get Alert |
| 05/27/2022 | Buy Now | 26.65% | SVB Leerink | Whit Mayo68% | $131 → $117 | Maintains | Market Perform | Get Alert |
| 04/29/2022 | Buy Now | 97.01% | Credit Suisse | A.J. Rice68% | $181 → $182 | Maintains | Outperform | Get Alert |
| 04/29/2022 | Buy Now | 94.85% | Raymond James | John Ransom76% | $200 → $180 | Maintains | Outperform | Get Alert |
| 04/29/2022 | Buy Now | 41.81% | SVB Leerink | Whit Mayo68% | $162 → $131 | Maintains | Market Perform | Get Alert |
FAQ
What is the target price for Amedisys (AMED) stock?
The latest price target for Amedisys (NASDAQ:AMED) was reported by Stephens & Co. on March 4, 2025. The analyst firm set a price target for $101.00 expecting AMED to rise to within 12 months (a possible 9.33% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Amedisys (AMED)?
The latest analyst rating for Amedisys (NASDAQ:AMED) was provided by Stephens & Co., and Amedisys reiterated their equal-weight rating.
When was the last upgrade for Amedisys (AMED)?
There is no last upgrade for Amedisys
When was the last downgrade for Amedisys (AMED)?
The last downgrade for Amedisys Inc happened on July 31, 2024 when Deutsche Bank changed their price target from $101 to $101 for Amedisys Inc.
When is the next analyst rating going to be posted or updated for Amedisys (AMED)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Amedisys, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Amedisys was filed on March 4, 2025 so you should expect the next rating to be made available sometime around March 4, 2026.
Is the Analyst Rating Amedisys (AMED) correct?
While ratings are subjective and will change, the latest Amedisys (AMED) rating was a reiterated with a price target of $101.00 to $101.00. The current price Amedisys (AMED) is trading at is $92.38, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.